RT Journal Article
SR Electronic
T1 Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancies and COVID-19: a longitudinal cohort and propensity score analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.29.21268525
DO 10.1101/2021.12.29.21268525
A1 Thomas Hueso
A1 Anne-Sophie Godron
A1 Emilie Lanoy
A1 Jérôme Pacanowski
A1 Laura I. Levi
A1 Emmanuelle Gras
A1 Laure Surgers
A1 Amina Guemriche
A1 Jean-Luc Meynard
A1 France Pirenne
A1 Salim Idri
A1 Pierre Tiberghien
A1 Pascal Morel
A1 Caroline Besson
A1 Rémy Duléry
A1 Sylvain Lamure
A1 Olivier Hermine
A1 Amandine Gagneux-Brunon
A1 Nathalie Freymond
A1 Sophie Grabar
A1 Karine Lacombe
A1 the HEMOPLASM Study Group
YR 2022
UL http://medrxiv.org/content/early/2022/01/01/2021.12.29.21268525.abstract
AB Patients with hematological malignancies and COVID-19 display a high mortality rate. In such patients, immunosuppression due to underlying disease and previous specific treatment impair humoral response, limiting viral clearance. Thus, COVID-19 convalescent plasma (CCP) therapy appears as a promising approach through the transfer of neutralizing antibodies specific to SARS-CoV-2.We report the effect of CCP in a cohort of 112 patients with hematological malignancies and COVID-19 and a propensity score analysis on subgroups of patients with B-cell lymphoid disease treated (n=81) or not (n=120) with CCP between 1 May 2020 and 1 April 2021. The overall survival of the whole cohort was 65% [56–74.9] and 77.5% [68.5–87.7] for patients with B-cell neoplasm. Prior anti-CD20 monoclonal antibodies therapy was associated with better overall survival whereas age, high blood pressure, and COVID-19 severity were associated with a poor outcome. After an inverse probability of treatment weighting approach, we observed in anti-CD20–exposed patients with B-cell lymphoid disease a decreased mortality of 63% (95% CI=31%–80%) in the CCP-treated group compared to the CCP-untreated subgroup, confirmed in the other sensitivity analyses.Convalescent plasma may be beneficial in COVID-19 patients with B-cell neoplasm who are unable to mount a humoral immune response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the program Emergency Support Instrument (ESI) of the European Commission (project CCPEFS, grant number 101021793) and Sorbonne UniversityAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of French Infectious Diseases Society gave ethical approval for this work (IRB number: 00011642)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors